Retirement Systems of Alabama Acquires 379,870 Shares of Pfizer Inc. $PFE

Key Points

• Retirement Systems of Alabama increased its Pfizer stake by 12.3% in Q4, buying 379,870 shares to hold 3,477,110 shares (about 0.06% of the company) valued at $86.58 million.
• Pfizer beat Q4 estimates with EPS of $0.66 versus $0.57 expected and revenue of $17.56 billion versus $16.93 billion, though revenue was down 1.2% year‑over‑year; the analyst consensus remains a Hold with a $28.19 average price target.
• Short‑term buying has been driven by optimism around Pfizer’s once‑monthly GLP‑1/weight‑loss candidate and its high dividend appeal, but accelerating competition (notably from Eli Lilly) presents a longer‑term risk.

Retirement Systems of Alabama grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 12.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,477,110 shares of the biopharmaceutical company's stock after acquiring an additional 379,870 shares during the period. Retirement Systems of Alabama owned about 0.06% of Pfizer worth $86,580,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in PFE. Fiduciary Alliance LLC lifted its stake in Pfizer by 46.4% in the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company's stock worth $3,701,000 after purchasing an additional 46,043 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Pfizer in the third quarter worth about $3,019,000. Vista Investment Partners LLC lifted its position in shares of Pfizer by 236.1% in the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company's stock worth $1,774,000 after buying an additional 48,900 shares in the last quarter. Money Concepts Capital Corp boosted its stake in Pfizer by 29.9% during the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company's stock valued at $6,325,000 after buying an additional 57,188 shares during the last quarter. Finally, Kepler Cheuvreux Suisse SA bought a new position in Pfizer during the third quarter valued at approximately $16,613,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

NYSE PFE opened at $27.75 on Tuesday. The business's 50 day moving average price is $26.88 and its 200-day moving average price is $25.72. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The company has a market cap of $157.80 billion, a P/E ratio of 20.41 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period last year, the company earned $0.63 earnings per share. Pfizer's revenue was down 1.2% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Barclays initiated coverage on Pfizer in a research note on Thursday, February 19th. They issued an "underweight" rating and a $25.00 price objective on the stock. BMO Capital Markets reissued an "outperform" rating and issued a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. Guggenheim upped their price target on shares of Pfizer from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Tuesday, March 24th. Daiwa Securities Group lowered shares of Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price objective for the company. in a research report on Thursday, February 12th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $28.19.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Market optimism around Pfizer’s once‑monthly GLP‑1/weight‑loss candidate and coverage by high‑profile commentators has driven short‑term buying interest — investors are revisiting Pfizer’s positioning in the obesity/GLP‑1 market. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: Longer‑term bullish commentary and retail coverage argue Pfizer’s diversified portfolio, pipeline and ability to pivot (including GLP‑1 work) make it an attractive buy for patient investors. This kind of coverage can sustain inflows beyond short‑term headlines. Prediction: Buying Pfizer Stock Today Could Set You Up for Life
• Positive Sentiment: Inclusion on lists of large‑cap stocks with high dividends highlights Pfizer’s income appeal; dividend support can attract conservative and yield‑seeking investors amid growth uncertainty. Pfizer (PFE) – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Spike in search and retail attention (tracked by Zacks) signals higher visibility and trading volume; increased attention can amplify moves in either direction depending on upcoming catalysts. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Consensus analyst rating remains a “Hold” (mixed buy/hold/sell split), reflecting balanced views on near‑term growth vs. pipeline uncertainty — this limits the likelihood of broad upgrades unless clinical or commercial news surprises to the upside. Pfizer Inc. NYSE: PFE Receives Consensus Recommendation of “Hold” from Analysts
• Negative Sentiment: Competitive moves from rivals — notably Eli Lilly’s large AI‑enabled drug discovery deal — underline accelerating competition and faster innovation cycles in diabetes/weight‑loss and other areas, a risk to Pfizer’s market share and margin outlook over time. Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.